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ABSTRACT
Despite a good initial response to front-line chemotherapy, majority of the 
ovarian cancer patients relapse with consecutive phases of recurrences; and nearly 
60% die within 5 years due to the development of a chemoresistant disease. This 
study investigated whether inhibition of the Janus kinase 2 (JAK2)-signal transducer 
and activator of transcription 3 (STAT3) pathway by momelotinib is sufficient in 
suppressing tumor burden and prolonging the disease-free survival period in a 
mouse model of ovarian cancer. We demonstrate that paclitaxel treatment enhanced 
JAK2/STAT3 activation which resulted in the enrichment of cancer stem cell (CSC)-
like phenotype in the surviving ovarian cancer cells in vitro and in in vivo mouse 
xenografts. Combined treatment with paclitaxel and momelotinib inhibited paclitaxel-
induced JAK2/STAT3 activation and CSC-like development in mice xenografts, and 
consequently reduced the tumor burden significantly greater than that achieved by 
paclitaxel-treatment alone. However, robust recurrent tumor growth with enhanced 
JAK2/STAT3 activation and CSC-like phenotype was observed in all mice groups 
after termination of treatments, but was delayed significantly in the paclitaxel and 
momelotinib treated group compared to other treatment groups. Daily oral gavage 
of momelotinib after termination of paclitaxel treatment showed sustained inhibition 
of tumor growth and a prolonged disease-free survival period in 50% of the mice. 
The other 50% of mice that developed tumors with ongoing momelotinib treatment 
also showed significantly increased survival benefit and a smaller tumor burden. 
These preliminary findings may have a profound clinical impact in developing an 
effective momelotinib-based ‘maintenance-therapy’ in ovarian cancer patients’ post-
chemotherapy treatment.
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INTRODUCTION
Despite improvements in the treatment for epithelial 
ovarian cancer over the last three decades, the mortality 
rate remains largely unchanged. Majority of the patients 
who achieve clinical response to paclitaxel and platinum-
based chemotherapy experience relapse and die within 5 
years of diagnosis [1]. Current chemotherapy treatments 
lead to substantial tumor regression in the majority 
of the ovarian cancer cases but they do not eliminate 
subpopulations of residual cancer stem cells (CSCs) 
which have been demonstrated to be responsible for 
the regrowth of tumors in the recurrent scenario [2–6]. 
Henceforth, recurrence occurs shortly after an otherwise 
apparently successful first line of treatment. Although 
targeting CSCs has gained increased popularity as a 
potential avenue to improve disease-free progression and 
overall survival in many cancers, the survival mechanisms 
of CSCs after chemotherapy treatments are still not fully 
understood [7, 8].
The JAK2/STAT3 pathway mediates the effects of 
growth factors and cytokines by regulating the expression 
of downstream gene expression [9]. In normal cells, 
STAT3 is transiently activated in response to specific 
growth factors and cytokines (e.g. IL6, GCSF, LIF, 
EGF). However, in cancers, including breast, ovarian 
and prostate, STAT3 is constitutively active in certain 
populations of tumor cells [10, 11]. The STAT3 pathway 
has been shown to be a prerequisite for the proliferation 
and maintenance of glioblastoma and breast cancer stem 
cells [12, 13], rapidly cycling intestinal stem cells [14], 
as well as ovarian cancer cells [3]. Coupling of the stem 
cell marker CD44 with the embryonic stem cell marker 
Nanog has been shown to be associated with the activation 
of STAT3 in ovarian cancer cells [15]. The activation of 
STAT3 in these cells resulted in multidrug resistance gene 
expression and concomitant chemoresistance. We and 
others have shown significantly enhanced expression of 
STAT3 in drug-resistant recurrent ovarian tumors derived 
from metastatic ovarian lesions and ascites-derived 
tumors, compared to primary tumors and chemonaive 
ascites-derived tumors [16–18]. The molecular signature 
of CSCs has also been associated with chemoresistant 
ovarian and other cancers [18, 19]. Hence, the JAK2/
STAT3 and CSC associated pathways are potential targets 
for the development of novel drugs aimed at suppressing 
their constitutive as well as ligand induced activation. 
In the last decade, several anti-STAT3 compounds have 
been identified to inhibit cancer-associated proliferation, 
inflammation and chemotherapy resistance [9, 10]. 
However, none of these compounds have shown effects 
on CSCs, which theoretically have been suggested to drive 
chemoresistance.
Previous studies from our group have demonstrated 
that intraperitoneal (ip) injection of in vitro chemotherapy-
treated ovarian cancer cells in nude mice resulted in 
the generation of a larger tumor burden with increased 
tumor staining of CSC-like cells compared to control 
untreated cells [3]. Nonetheless, in vitro treatment with a 
combination of chemotherapy and momelotinib (a potent 
ATP-competitive inhibitor of JAK1/2) substantially 
suppressed CSC-like cells and tumor burden in mice 
when these treated-cells were injected in mice [20]. In 
order to determine the pharmacological and toxicological 
parameters of chemotherapy and momelotinib treatment in 
vivo, subcutaneous inoculation of untreated ovarian cancer 
cells was performed in mice, which were subsequently 
treated ip with paclitaxel with or without daily oral gavage 
of momelotinib [4]. Consistent daily treatment with 
momelotinib and weekly paclitaxel resulted in a smaller 
subcutaneous tumor volume with significant reduction in 
CSC-like cells in mice xenografts compared to a group 
of mice treated with weekly paclitaxel alone [4]. The 
above studies are the first to demonstrate the efficacy of 
momelotinib as a CSC-targeted therapy for ovarian cancer.
The aim of this study was to evaluate the effect of 
momelotinib on the CSC phenotype in ovarian cancer 
cell line models in vitro and in an in vivo mouse model. 
The main objective was to evaluate the effect of treatment 
with momelotinib in combination with paclitaxel on the 
tumor burden, peritoneal dissemination and disease-free 
remission period in a mouse model. Two ovarian cancer 
cell lines representative of high-grade serous (HEY) and 
clear cell (TOV21G) ovarian carcinomas were chosen to 
determine the in vitro effect of paclitaxel with or without 
momelotinib. The HEY cell line was further examined 
in an in vivo mouse model to determine the effect of 
paclitaxel with or without momelotinib. This ‘proof of 
concept’ study demonstrates that the use of daily oral 
dosing of momelotinib as a ‘maintenance therapy’ after 
chemotherapy treatment not only prolongs the disease-
free remission period but also inhibits the peritoneal 
dissemination in a mouse model of ovarian cancer. The 
findings in this study therefore, warrant future clinical 
trials for comprehensive evaluation of momelotinib for the 
better management of ovarian cancer patients.
RESULTS
The addition of momelotinib suppressed 
paclitaxel-induced JAK2/STAT3 pathway 
activation in ovarian cancer cell lines
In this study, we explored the activation of JAK2/
STAT3 pathway in serous HEY and clear cell carcinoma 
TOV21G cell lines in vitro by Western Blot and 
immunofluorescence in response to the concentration 
of paclitaxel which inhibited cell growth by 50% (GI50) 
(HEY: 0.05ng/mL, TOV21G: 0.01ng/mL). HEY cell line 
demonstrated the highest expression of phosphorylated-
JAK2 (P-JAK2) following a 6 hour treatment (Figures 1 
and 2, A-C), while phosphorylated-STAT3 (P-STAT3) 
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peaked following a 24 hour treatment (Figures 1 and 2, D-
F). For TOV21G cell line, P-JAK2 and P-STAT3 expression 
began to peak following 24 hours of paclitaxel treatment 
(Supplementary Figures 1 and 2, A-F). In both HEY and 
TOV21G cells, P-JAK2 and P-STAT3 proteins were 
also observed in the nucleus of cells upon activation by 
paclitaxel (Figure 2, Supplementary Figure 2). These were 
mostly seen at 6 and 24 hours paclitaxel-treated samples, 
but were less prominent in 72 hour samples (Figure 2, 
Supplementary Figure 2). The expression of total (T)-JAK2 
and total (T)-STAT3 remained unchanged within 72 hours 
in response to paclitaxel treatment by immunofluorescence. 
However, Western blots showed massive down regulation 
of T-JAK2 and T-STAT3 expression at 72 hours-in HEY 
Table 1: Primer sequences of human oligonucleotides used in Quantitative Real-time PCR
Oligonucleotide Name Forward (F) 5′ - 3′
Reverse (R) 5′ - 3′
Primer Sequence (5′ - 3′) Size (bp)
EpCAM F CGT CAA TGC CAG TGT ACT TCA GTT G 301
R TCC AGT AGG TTC TCA CTC GCT CAG
Oct4A F CTC CTG GAG GGC CAG GAA TC 381
R CCA CAT CGG CCT GTG TAT AT
CD133 F ATT GGC ATC TTC TAT GGT TT 167
R GCC TTG TCC TTG GTA GTG T
18S F GTA ACC CGT TGA ACC CCA TT 153
R CCA TCC AAT CGG TAG TAG CG
Figure 1: JAK2 and STAT3 activation in HEY cells in response to paclitaxel treatment by Western blot. (A and D) Total 
cell lysates of untreated and cells treated with 0.05μg/mL of paclitaxel following 6, 24 and 72 hours of paclitaxel treatment were prepared 
and subjected to Western blot analysis using antibodies specific for P- or T-JAK2 and P- or T-STAT3. Total protein load was determined by 
stripping and re-probing the membranes with GAPDH. Images are representative of four independent cell lysate samples. Densitometric 
analyses of (B-C) P-JAK2 and T-JAK2; (E-F) P-STAT3 and T-STAT3 protein expression were determined by using Image J. The values 
represent the relative mean band intensity normalized to GAPDH loading control ± SEM of four independent experiments. Parametric one-
way ANOVA with Tukey’s post-test was used. Significance is indicated by *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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cells (Figures 1A and 1D). In TOV21G cells, no change in 
the expression of total JAK2 and STAT3 was observed by 
Western blots or immunofluorescence.
Optimal inhibition of paclitaxel-induced JAK2/
STAT3 phosphorylation was observed with 1 μM 
momelotinib treatment at 24 hours by Western blot in 
HEY cells (Supplementary Figure 3A-3D). There was 
no significant difference in the expression of T-JAK2 
and T-STAT3 in all treatment groups (Supplementary 
Figure 3C-3D). Significant inhibition of JAK2/STAT3 
activation by 1μM momelotinib in both HEY and 
TOV21G cell lines was demonstrated by Western blot 
and immunofluorescence (Figures 3 & 4) (Supplementary 
Figures 4 & 5). Momelotinib in the presence of paclitaxel 
also inhibited the nuclear translocation of P-JAK2 
and P-STAT3 to nucleus (Figure 4 and Supplementary 
Figure 5).
Momelotinib significantly suppressed the 
development of CSC-like markers associated 
with paclitaxel treatment in ovarian cancer cell 
lines
To evaluate in vitro the effects of momelotinib 
treatment on ovarian CSC-like cells, we studied the 
changes in the cell surface expression of ovarian CSC 
markers in HEY and TOV21G cell lines in response to 
paclitaxel, momelotinib or paclitaxel + momelotinib by 
flow cytometry. Following paclitaxel treatment, both HEY 
and TOV21G cell lines demonstrated significant increase 
in cell surface markers of EpCAM, CD44 and CD133 as 
observed by flow cytometry, which were significantly 
inhibited with the addition of momelotinib (Figure 5A 
and Supplementary Figure 6). This was consistent with 
the significantly increased mRNA expression of CD133, 
Figure 2: JAK2 and STAT3 activation in HEY cells in response to paclitaxel treatment by immunofluorescence. 
(A and D) Expression and localization of activated P-JAK2/STAT3 and T-JAK2 /STAT3 in ovarian cancer HEY cell line following 6, 24 
and 72 hours treatment with paclitaxel was determined by immunofluorescence staining. Untreated and treated cells were assessed for 
the expression of P-JAK2, T-JAK2, P-STAT3 and T-STAT3 by immunofluorescence using rabbit and mouse polyclonal and monoclonal 
antibodies as described in the Materials and Methods section. Staining was visualized using the secondary Alexa 590 (red) and Alexa 488 
(green) fluorescent-labelled antibodies and nuclei were detected by DAPI (blue) staining. Images are representative of three independent 
experiments. Magnification was 400X; scale bar = 250μm. Quantification of (B-C) P-JAK2 and T-JAK2; (E-F) P-STAT3 and T-STAT3 
fluorescent intensity was determined by using Image J. Results are expressed as the percentage of the average fluorescent intensity value 
relative to untreated cells ± SEM of three independent experiments. Parametric One-way ANOVA with Tukey’s post-test was used. 
Significance is indicated by *p<0.05, **p<0.01.
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EpCAM and Oct4A in response to paclitaxel treatment, 
and their significant reduction with the addition of 
momelotinib in HEY cells (Figure 5C).
The effect of momelotinib in a mouse model: A 
three phase study
Phase 1: Daily momelotinib administration in 
conjunction with weekly paclitaxel significantly 
reduced in vivo expression of CSC markers and 
associated tumorigenicity of HEY cells in mice
To investigate the in vivo anti-tumorigenic 
effect following the administration of momelotinib in 
conjunction with paclitaxel, all mice in Phase 1 study 
were culled at the endpoint of the control untreated mice 
and their tumor burden was measured. Thirty-five days 
post-inoculation of cells, all treated mice were subjected to 
euthanasia at the humane endpoint of the control untreated 
mice. Upon dissection, multiple macroscopic tumor 
deposits of volume (2 - 32 mm3) were observed primarily 
in the liver, pancreas and bowels, and several smaller 
tumor nodules (0.3 - 1.8 mm3) were also found throughout 
the peritoneal cavity of the control untreated mice 
(Figure 6A). Mice treated with paclitaxel or momelotinib 
alone developed macroscopic tumors (2.5 - 22 cm3 and 2.5 
- 15 mm3 respectively) that were found mainly in the liver 
and bowels, and smaller tumor nodules (0.6 - 1.8 mm3 
and 0.6 - 1.3 mm3 respectively) seen scattered throughout 
the peritoneal cavity. Mice treated with a combination 
of paclitaxel and momelotinib developed small tumor 
nodules (0.01 - 1.3 mm3) and fewer macroscopic tumors (2 
- 6.4 mm3) that were discovered primarily in the bowels. 
Overall, fewer tumors were found and isolated from each 
mice in the treatment group compared to control untreated 
mice (Figure 6A).
We next compared the tumor burden between all 
mice in Phase 1. Control untreated mice developed the 
largest tumor burden compared to all groups, with a mean 
of 13.6 ± 1.6% standardised to body weight (Figure 6B). 
No significant difference was observed in the average 
tumor burden between mice that were treated with weekly 
paclitaxel compared to control untreated mice. However, 
mice treated with the combination had significantly 
smaller tumor burden (3.2 ± 1.1%) compared to mice 
treated with weekly paclitaxel (10.1 ± 0.5%) and the 
control group (13.6+1.6%). Paclitaxel, momelotinib or 
Figure 3: Effect of paclitaxel and/or momelotinib treatment on the activation of JAK2 and STAT3 in HEY cells by 
Western blot. (A and D) Total cell lysates of untreated cells and cells treated with 0.05μg/mL of paclitaxel (Pac) with or without 1μM 
of momelotinib (Mom) for 24 hours were extracted and subjected to immunoblot analysis using antibody specific for P-JAK2/STAT3 or 
T-JAK2/STAT3. Total protein load was determined by stripping and re-probing the membranes with GAPDH. Images are representative 
of three independent lysate samples. Densitometric analyses of (B-C) P-JAK2 and T-JAK2 and (E-F) P-STAT3 and T-STAT3 protein 
expression were determined by using Image J. The values represent the relative mean of band intensity normalized to GAPDH loading 
control ± SEM of three independent experiments. Parametric One-way ANOVA with Tukey’s post-test was used. Significance is indicated 
by **p<0.01, ***p<0.001.
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a combination of both treatments were well tolerated in 
mice without any adverse toxicological signs throughout 
the experiment. No significant difference in the average 
body weight was observed between all groups throughout 
this study.
Histological examination of the tumor xenografts 
revealed morphological features resembling high grade 
serous carcinoma in women with ovarian cancer (Figure 
6C). In general, the isolated mouse tumors from all groups 
displayed extensive cellular budding, aneuploidy, very 
large and rounded nuclei and branches of stromal and 
papillae structures. Diffuse papillary projections with 
large irregular size and disseminated pattern suggestive of 
malignancy were seen commonly in the tumors isolated 
from paclitaxel-treated mice compared to all other groups, 
while a much lesser extent of papillary projection was 
seen in the tumors of mice treated with a combination of 
paclitaxel and momelotinib.
To determine whether the administration of 
paclitaxel and momelotinib had any in vivo effect on tumor 
metastasis, mice organs (liver, pancreas, spleen, kidney, 
small bowel and large bowel) were collected and subjected 
to H&E staining. Tumor invasion was seen in the pancreas 
and bowels of control mice and those treated with either 
weekly paclitaxel or daily momelotinib. However, liver 
invasion was seen only in the control mice group. Mice 
that were treated with a combination of weekly paclitaxel 
and daily momelotinib had tumor invasion that involved 
only the small bowel (Figure 7). Although tumors were 
visible on the kidney wall of untreated and paclitaxel-
treated mice, no visible tumor infiltration was seen.
Immunohistochemistry analysis of the xenografts of 
mice treated with paclitaxel showed significantly higher 
P-JAK2 and P-STAT3 expression when compared to 
the untreated group, while no significant difference was 
observed for T-JAK2 and T-STAT3 staining between all 
Figure 4: Effect of paclitaxel and/or momelotinib treatment on JAK2 and STAT3 activation in HEY cells by 
immunofluorescence. (A and D) Expression and localization of the JAK2 and STAT3 activation in ovarian cancer HEY cells in 
response to treatments with 0.05μg/mL of paclitaxel (Pac) with or without 1μM of momelotinib (Mom) for 24 hours were determined by 
immunofluorescence staining. Untreated and treated cells were assessed for the expression of P-JAK2/STAT3 and T-JAK2/STAT3 using 
rabbit and mouse polyclonal and monoclonal antibodies as described in the Materials and Methods section. Staining was visualized using 
the secondary Alexa 590 (red) and Alexa 488 (green) fluorescent-labelled antibodies and nuclei were detected by DAPI (blue) staining. 
Images are representative of three independent experiments. Magnification was 400X; scale bar = 250μm. Quantification of (B-C) P-JAK2 
and T-JAK2, and (E-F) P-STAT3 and T-STAT3 fluorescent intensity was determined using Image J. Results are expressed as the percentage 
of the average fluorescent intensity value relative to untreated cells ± SEM of three independent experiments. Parametric One-way ANOVA 
with Tukey’s post-test was used. Significance is indicated by *p<0.05, **p<0.01, ****p<0.0001.
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groups (Figure 8). Treatment with paclitaxel + momelotinib 
or momelotinib on its own resulted in tumors that expressed 
significantly reduced P-JAK2 and P-STAT3 when compared 
to the group that received paclitaxel treatment.
To further analyse the tumor phenotype following 
administration of momelotinib and paclitaxel treatment 
in mice, the resected tumors of mice in Phase 1 were 
subjected to immunohistochemical analysis for the 
expression of cancer antigen 125 (CA125), proliferative 
marker Ki67, cluster of differentiation 31 (CD31), and 
CSC-like markers c-Kit and Oct3/4 (Figure 9). Significant 
increase in CA125, Ki67 and CD31 staining was observed 
in the xenograft derived from paclitaxel-treated mice 
compared to the xenograft of control untreated mice 
(Figure 9). Consistent with these results, tumors from the 
paclitaxel-treatment group had significantly increased 
expression of c-Kit and Oct3/4 compared to the untreated 
control group (Figure 9). On the other hand, the addition 
of momelotinib to paclitaxel significantly reduced 
CA125 tumor staining by 2.5-fold when compared to the 
xenografts of mice treated with paclitaxel alone. Mice that 
received daily momelotinib alone or in conjunction with 
weekly paclitaxel had tumors that exhibited significantly 
reduced Ki67 and CD31 staining when compared to that 
of the control untreated mice and paclitaxel-treated mice 
(Figure 9). Tumors derived from the group that received 
momelotinib treatment showed a reduction in c-Kit 
expression compared to paclitaxel-treated groups. The 
Figure 5: Analysis of the expression of CSC-like surface markers in HEY cells treated with paclitaxel and/or 
momelotinib. (A) Cell surface expression of EpCAM, CD44 and CD133 in ovarian cancer HEY cells in response to 24 hours treatments 
with 0.05μg/ml paclitaxel (Pac), 1μM momelotinib (Mom) or a combination of both (Pac+Mom) were determined by flow cytometry. 
Untreated and treated cells were incubated with primary antibodies specific for EpCAM, CD44-PE, CD133-PE or IgG, followed by anti-
mouse-PE secondary antibody for EpCAM detection. Histograms are representative of four independent experiments. (B) Semi-quantitative 
analysis of the arbitrary fluorescent expression of CSC-like markers was performed. Results are expressed as the mean arbitrary fluorescent 
expression of the markers of interest relative to negative control IgG ± SEM of four independent experiments. Parametric One-way ANOVA 
with Tukey’s post-test was used. Significance is indicated by *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (C) Absolute quantification of 
the mRNA expression of CSC-like markers in ovarian cancer HEY cells in response to 24 hour treatments with 0.05μg/ml paclitaxel (Pac), 
1μM momelotinib (Mom) or a combination of both were determined by qRT-PCR. RNA was extracted from the untreated and treated cells, 
and qRT-PCR was performed as described in the Materials and Methods section. Results are presented as the mean absolute value of the 
gene of interest normalized to the 18S housekeeping gene ± SEM of four independent samples in triplicate. Parametric One-way ANOVA 
with Tukey’s post-test was used. Significance is indicated by *p<0.05, **p<0.01.
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group that received paclitaxel + momelotinib produced 
tumors that displayed a significant reduction in c-Kit and 
Oct3/4 staining when compared to that of control untreated 
and paclitaxel-treated mice (Figure 9).
Phase 2: Termination of paclitaxel, momelotinib or 
a combination of both treatments resulted in robust 
tumor development
In Phase 2, mice were treated as in Phase 1, and 
termination of all treatments was performed at the endpoint 
of Phase 1. These mice were then allowed to survive until 
the experimental endpoint of each mouse was achieved. 
The survival period, tumor burden and dissemination 
of tumor in mice were noted in Phase 2. Overall, all 
treated-groups survived longer than the control untreated 
group (Figure 10A). Mice treated with a combination of 
paclitaxel and momelotinib survived the longest when 
compared to all groups, 2 weeks longer compared to 
control untreated mice. While the difference between 
paclitaxel only treated and momelotinib only treated mice 
was not significant, both these groups survived five days 
longer compared to the control untreated group (Figures 
10A).
Termination of paclitaxel, momelotinib or 
a combination of both treatments resulted in the 
development of multiple tumors of varying sizes 
throughout the peritoneal cavity similar to that 
observed in control untreated mice. Overall, there was 
no significant difference in the average tumor burden 
between all groups in Phase 2 (Figure 10B). Similar to 
Phase 1 study, the morphological features of tumors 
in mice resembled high grade serous carcinoma in 
women (Supplementary Figure 7A). The presence of 
larger stromal projections was more common in the 
Figure 6: Tumor burden and histology of tumor xenografts derived from mice intraperitoneally injected with HEY 
cells and treated with either paclitaxel, momelotinib or a combination of both (Phase 1). (A) Representative images of mice 
dissection and resected tumors from control untreated mice and mice treated with weekly paclitaxel, daily momelotinib, or a combination 
of paclitaxel and momelotinib. All mice treatment was initiated 19 days post-inoculation with HEY cells. At the endpoint of control 
untreated mice at 35 days post-inoculation, all mice were subjected to euthanasia, dissected and their tumors were excised. Arrows indicate 
the presence of tumors. (B) Quantification of tumor burden is represented by the percentage of the weight of tumor relative to the weight 
of mice from which the tumor was isolated. Data is presented as mean ± SEM (n=4 control untreated mice, n=3 mice/treated group). 
Parametric One-way ANOVA with Tukey’s post-test was used for statistical analysis. Significance is indicated by *p<0.05, **p<0.01. (C) 
Representative images of H&E stained tumor xenografts derived from control untreated mice and mice treated with either weekly paclitaxel 
(Pac), daily momelotinib (Mom) or combination of paclitaxel and momelotinib (Pac+Mom) (n=3/group). Arrows indicate the presence of 
papillary projections. Magnification 400x, scale bar = 10μm.
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tumors isolated from mice with terminated paclitaxel 
and terminated momelotinib treatment, while fewer 
and smaller stromal structures were seen in the tumors 
of mice with terminated combined treatments of 
paclitaxel and momelotinib. In addition to the bowel 
invasion observed in Phase 1, tumor invasion into 
the liver and pancreas was also observed in mice 
with terminated paclitaxel or momelotinib alone. 
On the other hand, tumor invasion was observed in 
the pancreas, spleen and bowels of mice in which 
paclitaxel+momelotinib treatment was terminated 
(Supplementary Figure 7B).
Overall, immunohistochemical staining of 
xenografts revealed significant increase in P-JAK2 
and P-STAT3 staining in the xenografts of mice with 
terminated momelotinib or a combination of paclitaxel and 
momelotinib when compared to their respective groups in 
the Phase 1 study (Figures 10C, 10D and Supplementary 
Figure 8). However, no statistical significance was 
detected between the paclitaxel groups in both Phase 1 
and Phase 2 studies and between the three treatments 
terminated groups in Phase 2 (Figures 10C and 10D). No 
significant difference was detected in the tumor staining 
of T-JAK2 and T-STAT3 between all groups in Phase 1 
and 2 studies.
Consistent with P-JAK2/P-STAT3 staining, 
immunohistochemical analysis for CSC markers c-Kit 
and Oct3/4 as well as Ki67 and CD31 were found to 
be significantly enhanced in the xenografts derived 
from mice with terminated paclitaxel, momelotinib, 
and paclitaxel+momelotinib compared to their 
respective groups in Phase 1 study (Figures 10E, 
10F and Supplementary Figures 8 and 9). The tumor 
staining of CA125 was significantly higher in mice 
with terminated paclitaxel compared to the paclitaxel 
group in Phase 1; but remained unchanged between the 
paclitaxel+momelotinib groups in Phase 2 and Phase 
1 studies (Supplementary Figure 9). No significant 
difference in c-Kit, Oct3/4, Ki67, CD31 and CA125 
staining was detected between the three treatment-
terminated groups in Phase 2 study (Figures 10E, 10F 
and Supplementary Figures 8 and 9).
Figure 7: Histological assessment of pancreatic, hepatic, small and large bowel infiltration by tumors developed in 
mice inoculated with HEY cells in Phase 1. Representative images of H&E stained pancreas, liver, small and large bowel derived 
from untreated mice and mice treated with either weekly paclitaxel (Pac), daily momelotinib (Mom) or combination of paclitaxel and 
momelotinib (Pac+Mom) (n=3/group). Arrows indicate tumor cells invading respective organs. Magnification 200x, scale bar = 10μm.
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Phase 3: Continuous administration of momelotinib 
after termination of paclitaxel treatment significantly 
enhanced the disease-free survival time in 50% of mice
In Phase 3, Groups 2 and 3 mice survived 
significantly longer than control and Group 1 mice 
(Figure 11A). Kaplan Meier analysis of survival revealed 
that control untreated mice survived 23-35 days post-
inoculation of HEY cells, Group 1 mice survived 25-35 
days, while Group 2 mice with terminated paclitaxel 
and momelotinib-combined treatment survived 24-
50 days post-inoculation of HEY cells (Figure 11A). 
Interestingly, Group 3 mice with terminated paclitaxel 
but ongoing daily momelotinib treatment survived 33-
91 days post-inoculation, with 50% of mice surviving 
until the designated endpoint at 91 days post-inoculation. 
Four out of the nine mice in Group 3 that received 
ongoing momelotinib treatment developed tumors and 
subsequently survived 33-68 days post-inoculation with 
HEY cells (Figure 11A). However, the other 5 out of 9 
mice survived until the designated endpoint at 91 days 
post-inoculation. Only one small tumor nodule was found 
on the bowel of one mouse, while no tumor was seen in 
the rest of the mice in this group that survived 91 days 
post HEY cell inoculation. Overall, Group 3 mice that 
received ongoing daily momelotinib developed an average 
tumor burden that was significantly smaller compared to 
the average tumor burden generated in control untreated 
mice and Group 2 mice (>3 fold less in both cases) (Figure 
11B). The tumor burden in Group 1 was also significantly 
smaller than the tumor burden in the control group 
(approximately 2-fold). However, no significant difference 
in the tumor burden was observed between the control and 
Group 2 mice and Groups 1 and 3 mice (Figure 11B).
Immunohistochemical analysis of P-STAT3, 
T-STAT3, CA125, c-Kit and Oct3/4 performed on the 
resected tumors of Group 3 mice was compared to the 
tumor staining of control untreated mice and mice from 
Groups 1 and 2 (Figures 11C-11F). The tumor staining 
of P-STAT3 in Group 3 mice was significantly lower 
when compared to the tumor staining in control untreated 
mice and Group 2 mice, while no significant difference 
was observed when compared to Group 1 mice (Figure 
11C). No significant difference was detected in T-STAT3 
staining between all groups (Supplementary Figure 10). 
Ongoing momelotinib treatment in Group 3 mice resulted 
in tumors with significantly reduced c-Kit and Oct3/4 
Figure 8: Immunohistochemical analysis of P-JAK2, T-JAK2, P-STAT3 and T-STAT3 expression in tumor xenografts 
derived from mice intraperitoneally injected with HEY cells in Phase 1. (A) Representative images of P-JAK2, T-JAK2, 
P-STAT3 and T-STAT3 immunohistochemistry staining in paraffin embedded tumor xenografts derived from control untreated mice, and 
mice treated with either weekly paclitaxel (Pac), daily momelotinib (Mom) or a combination of paclitaxel and momelotinib (Pac+Mom). 
Magnification 200x, scale bar = 200μm. (B) Quantification of P-JAK2 and P-STAT3 DAB staining was performed using Fiji software as 
described in the Materials and Methods. Results are expressed as the average DAB reading of positively-stained tumor cells subtracted 
by the average DAB staining of the negatively-stained cells for each xenograft ± SEM (n=3/group). Parametric One-way ANOVA with 
Tukey’s post-test was used. Significance is indicated by *p<0.05, **p<0.01, ***p<0.001.
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staining when compared to Group 2 mice (Figures 11E 
and 11F). However, the average DAB staining of CA125 
in Group 3 mice was significantly enhanced when 
compared to control untreated and mice in Groups 1 and 
2 (Figure 11D).
DISCUSSION
Targeted agents have been the primary focus in 
enhancing the treatment regime for patients with recurrent 
ovarian cancer [21]. We have previously shown that 
ascites-derived ovarian tumor cells isolated from recurrent 
patients treated with chemotherapy have significantly 
higher expression of activated JAK2/STAT3 pathway 
compared to the tumor cells isolated from the ascites of 
chemonaive patients [22]. In this study, we show a similar 
up-regulation of activated JAK2/STAT3 pathway, and 
concomitant significant increase in the expression of 
CSC-like markers in HEY and TOV21G ovarian cancer 
cell lines in response to paclitaxel treatment in vitro. 
Paclitaxel-induced JAK2/STAT3 activation was inhibited 
significantly by momelotinib, which concurrently 
inhibited the CSC-like marker expression in both HEY and 
TOV21G cell lines. These results suggest an association 
between the activation of JAK2/STAT3 pathway and the 
emergence of CSCs in ovarian cancer cells in response 
to paclitaxel treatment. In addition to the in vitro studies, 
we also demonstrate that paclitaxel treatment significantly 
enhanced the activation of the JAK2/STAT3 pathway and 
CSC-like phenotype in the xenografts of mice injected 
with a serous human ovarian cancer HEY cell line. Despite 
a reduction in the tumor burden, paclitaxel treatment 
generated an aggressive tumor phenotype in HEY cell 
injected mice, as evidenced by significantly enhanced 
CA125, Ki-67 and CD31 expression in mice xenografts 
when compared to that of control untreated mice. As 
Figure 9: Immunohistochemical analysis of CA125, Ki67, c-Kit, Oct3/4 and CD31 expression in tumor xenografts 
derived from mice intraperitoneally injected with HEY cells in Phase 1. (A) Representative images of CA125, Ki67, c-Kit, 
Oct3/4 and CD31 immunohistochemistry staining in paraffin embedded tumor xenografts derived from control untreated mice and mice 
treated with either weekly paclitaxel (Pac), daily momelotinib (Mom) or a combination of paclitaxel and momelotinib (Pac+Mom). 
Magnification 200x, scale bar = 200μm. (B) Quantification of CA125, Ki67, c-Kit, Oct3/4 and CD31 DAB staining was performed using 
Fiji software as described in the Materials and Methods. Results are expressed as the average DAB reading of positively-stained tumor 
cells subtracted by the average DAB staining of the negatively-stained cells for each xenograft ± SEM (n=3/group). Parametric One-way 
ANOVA with Tukey’s post-test was used. Significance is indicated by *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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a result, the disease-free survival period of mice after 
termination of paclitaxel treatment was short-lived, due 
to the increase in tumor burden in mice. These scenarios 
are frequently mimicked in the clinical settings where 
high-grade serous ovarian cancer patients develop highly 
aggressive recurrent disease within a short time span after 
successful front line chemotherapy treatment [23].
The addition of daily momelotinib to weekly 
paclitaxel treatment significantly inhibited the JAK2/
STAT3 activation and CSC-like phenotypes in mice 
tumors. This was consistent with the significantly reduced 
tumor burden and intraperitoneal tumor metastasis 
in mice. However, the discontinuation of paclitaxel 
and momelotinib treatment no longer suppressed 
JAK2/STAT3 activation and CSC-like development, 
thus allowing the resumption of tumor growth and 
dissemination. On the other hand, ongoing suppression 
of JAK2/STAT3 activation with daily momelotinib 
administration in Phase 3 as a ‘maintenance therapy’ 
substantially reduced the tumor burden, and drastically 
improved the disease-free survival in 50% of the mice; 
while the other 50% mice demonstrated significantly 
less tumor burden compared to control and Group 2 
mice tumors and had a significantly prolonged disease-
free survival period. These observations support the 
notion that a chemotherapy-triggered microenvironment 
Figure 10: Survival analysis and tumor burden of mice in Phase 2 study; quantitative comparison of P-JAK2, P-STAT3, 
c-Kit and Oct3/4 immunohistochemical analysis of tumor xenografts derived from mice in Phase 1 and 2 studies. (A) 
Kaplan-Meier survival analysis of control untreated mice (yellow line), mice treated with either weekly paclitaxel (red dotted line), daily 
momelotinib (green dotted line) or a combination of paclitaxel and momelotinib (blue dotted line) in Phase 2. Parametric One-way ANOVA 
with Tukey’s post-test was used. Significance is indicated by **p<0.01, ***p<0.001. (B) Quantification of tumor burden is represented by 
the percentage of the weight of tumor (g) relative to the weight of mice (g) from which the tumor was isolated. Data is presented as mean 
± SEM (n=4 control untreated mice, n=5 treated mice/group). (C-F) Comparative quantification of P-JAK2, P-STAT3, c-Kit and Oct3/4 
DAB staining in mice tumor xenografts between Phase 1 and 2. Results are expressed as the average DAB reading of positively-stained 
tumor cells subtracted by the average DAB staining of the negatively-stained cells for each xenograft ± SEM (n=3/group). Parametric One-
way ANOVA with Tukey’s post-test was used to compare between the similar mice groups of Phases 1 and 2. Significance is indicated by 
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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provokes the escalation of resistant progenies that express 
the activated JAK2/STAT3 pathway with CSC-like 
arsenals to tackle the cytotoxic effects of chemotherapy; 
while cells expressing subtle/low JAK2/STAT3 activation 
succumb to chemotherapy treatment. However, if the 
suppression of an activated JAK2/STAT3 pathway can 
be sustained by momelotinib, tumor growth can be 
repressed which can result in a prolonged disease-free 
survival period. In this context, a recent manuscript has 
demonstrated large primary tumors and wide-spread 
metastases in mice injected with ascites-derived ovarian 
cancer cells with high P-STAT3 status compared to mice 
injected with low P-STAT3 status of ascites derived 
tumor cells [24]. These studies further support the 
association between elevated P-STAT3 signalling and the 
facilitation of ovarian tumorigenesis. Hence, combination 
therapies that include JAK2/STAT3 and CSC-specific 
targeted agents and a non-CSC-targeted agent such as 
chemotherapy, may be a more effective approach for the 
treatment of ovarian cancer [25–27].
Figure 11: Survival analysis and tumor burden of mice with ongoing momelotinib treatment in Phase 3; quantitative 
comparison of P-STAT3, CA125, c-Kit and Oct3/4 immunohistochemical analysis of tumor xenografts derived from 
mice in Phase 3. (A) Kaplan-Meier survival analysis of control untreated mice (yellow line), Group 1 mice (red dotted line), Group 2 
mice (green dotted line) and Group 3 mice (blue dotted line). All mice were treated with a combination of paclitaxel and momelotinib. 
Group 1 mice were culled at the endpoint of control untreated mice. Groups 2 and 3 mice were followed until they reached their individual 
endpoints or until the designated endpoint of this study at 91 days post-inoculation. Parametric One-way ANOVA with Tukey’s post-test 
was used. Significance is indicated by ***p<0.001. (B) Quantification of tumor burden is represented by the percentage of the weight of 
tumor (g) relative to the weight of mice (g) from which the tumor was isolated. Data is presented as mean ± SEM (n=9/group). Parametric 
One-way ANOVA with Tukey’s post-test was used. Significance is indicated by *p<0.05, ***p<0.001. (C-F) Quantification of P-STAT3, 
CA125, c-Kit and Oct3/4 DAB staining in paraffin embedded tumor xenografts derived from mice in Phase 3. Results are expressed as 
the average DAB reading of positively-stained tumor cells subtracted by the average DAB staining of the negatively-stained cells for each 
xenograft ± SEM (n=3/group). Parametric One-way ANOVA with Tukey’s post-test was used to compare between the similar mice groups 
of Phase 3. Significance is indicated by **p<0.01, ***p<0.001, ****p<0.0001.
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The first identification of ovarian CSC was reported 
in the ascites of an ovarian cancer patient, which was 
derived from a single cell and was shown to sequentially 
propagate tumors over several generations [28]. Since 
then CSCs have been isolated from ovarian tumors and 
cell lines by using identifiable cell surface and non-
Figure 12: Proposed clinical outcome that may occur in response to treatment with paclitaxel, momelotinib, combination 
of paclitaxel and momelotinib, and momelotinib maintenance therapy. CSCs are a small subset of tumor cells that are 
accountable for tumor regeneration and recurrence post-treatment. The JAK2/STAT3 signalling pathway is believed to be associated with 
the regulation of CSC-like development, thus targeting this pathway may eliminate CSCs and improve treatment outcome. (A) Treatment 
with weekly paclitaxel led to substantial reduction of tumor burden but increased JAK2/STAT3 activation and CSCs in the residual cells, 
thus resulting in tumor regeneration towards recurrence. (B) Treatment with daily momelotinib alone showed no effect on JAK2/STAT3 
activation but failed to eliminate CSCs, resulting in tumor regeneration towards recurrence. (C) Treatment with a combination of paclitaxel 
and momelotinib effectively suppressed JAK2/STAT3 activation and targeted CSCs. However, the discontinuation of paclitaxel and 
momelotinib-combined treatment resulted in the re-activation of JAK2/STAT3 and re-establishment of CSCs, leading to tumor regeneration 
towards recurrence. On the other hand, maintenance therapy with daily momelotinib treatment resulted in tumor regression until to a point 
of total tumor eradication in 50% of mice.
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surface markers commonly used in solid malignancies. 
CSCs in these studies have been isolated depending on 
the distinct pattern of surface markers such as CD44, 
EpCAM, CD133, CD117 (c-Kit), Thy1, CD24, etc. [2, 
7, 29–33] and non-surface markers, such as aldehyde 
dehydrogenase [34]. Even though CSCs sorted on the basis 
of these markers have shown the potential to have ‘CSC 
characteristics’ (such as, ability to self-renew, resistance 
to therapy, develop tumors with as low as 100 cells, etc), 
their significance in the clinical setting remains unknown. 
Among the CSC markers, CD44, EpCAM, c-Kit, CD133, 
Oct3/4 have been shown to be abundantly expressed in 
ovarian carcinomas, metastatic and recurrent tumors. 
Additionally, their high expression has been correlated 
with resistance to chemotherapy, shorter disease-free 
and overall survival [2, 7, 29, 35]. Clinical trials using 
monoclonal anti-human antibodies and small molecule 
inhibitors against some of these CSC-associated markers 
are in progress but their application in the clinical setting 
remains unknown [2, 7, 29]. In this study, CD44, EpCAM, 
c-Kit and CD133 were used as CSC markers to study the 
responses of paclitaxel and/or momelotinib treatments in 
in vitro ovarian cancer cell lines. However, most of the 
antibodies used for the in vitro characterization of these 
CSCs could not be used for mouse xenografts due to their 
lack of specificity on paraffin-embedded tumor sections, 
resulting in either a strong background staining or no 
signal on most xenografts. Hence, an effort was made to 
analyze and quantify the markers (such as CA125, CD31, 
Ki67, c-Kit and Oct3/4) which would give meaningful 
results consistent with ovarian cancer progression.
CA125 (also known as MUC16) is a type-1 
transmembrane glycoprotein that is up-regulated in the 
blood and tumors of many cancer patients, including 
ovarian cancer and is associated with poor prognosis [36, 
37]. CA125 is routinely used to diagnose, screen and 
predict treatment outcomes in ovarian cancer patients 
[36, 38]. CA125 know down studies in breast, ovarian 
and pancreatic cancers have shown its association in 
imparting tumorigenic, metastatic, chemoresistant and 
anti-apoptotic functions in cancer cells [39–44]. In 
addition, the ectopic expression of different lengths of 
carboxyl terminal fragments of CA125 in cancer cells 
has shown to increase metastatic and chemoresistant 
properties, suggesting that these fragments may be crucial 
in generating these functions in cancer cells [42, 45]. A 
recent study has demonstrated endogenous expression of 
a carboxy terminal cleaved 17 kDa MUC16-Cter fragment 
in normal human bronchial cells [45]. Forced expression 
of a 17 kDa MUC16-Cter fragment in pancreatic cancer 
cells mediated nuclear translocation of JAK2 which 
preferentially phosphorylated tyrosine 41 of histone H3 
(H3Y41) in a STAT-independent manner and up regulated 
stemness specific genes LMO2 [45, 46] and NANOG [46, 
47]. MUC16-Cter also mediated ALDH+ cancer stem cell 
enrichment which induced tumorigenic, metastatic and 
drug resistant properties in pancreatic cancer cells [48]. 
Even though, a non-canonical translocation of activated 
JAK2 to nucleus was observed in response to paclitaxel 
treatment in HEY cells, it remains unknown if paclitaxel-
induced JAK2 translocation to nucleus is associated with 
the increased expression of a carboxy-terminal fragment 
of CA125 associated with CSC specific genes.
The reduction of tumor growth in a mouse model 
with the addition of a novel inhibitor for JAK2 kinase, 
momelotinib, had a significant effect on the expression 
of CD31 in resulting xenografts. We demonstrate that 
paclitaxel-primed surviving tumor cells not only progress 
towards CSC-like cells but also drive tumor vascularisation 
as portrayed by enhanced CD31 expression and dominant 
papillary projections in paclitaxel-treated mice xenografts. 
However, the addition of momelotinib to paclitaxel 
impaired that effect as indicated by the reduction in CD31 
expression and less stromal diffusion by histology. This 
may be one of the driving factors that significantly delays 
tumor progression in the paclitaxel+momelotinib group, 
compared to the paclitaxel or momelotinib treatment 
groups in Phase 2 study and in the ongoing momelotinib 
treatment group in Phase 3 study. Even though these 
results are based on a mouse model using one ovarian 
cancer cell line, it augments valuable information about 
the effect of momelotinib in combination with paclitaxel 
on intraperitoneal ovarian tumor progression, and provides 
a stepping stone for future studies using other ovarian 
cancer cell lines and ideally primary ovarian cancer cells 
isolated from ovarian tumors and ascites of ovarian cancer 
patients.
CONCLUSION
This study is the first to describe the effectiveness 
of momelotinib, where prolonged daily treatment of 
momelotinib by oral gavage as a ‘maintenance therapy’ 
significantly improved the disease-free and overall 
survival in a mouse model of human ovarian cancer. 
The fact that 50% of mice were tumor-free for 91 
days post HEY cell transplantation by daily dosing of 
momelotinib after paclitaxel treatment had terminated, 
indicates a remarkable improvement in the disease-
free and overall survival. In addition, the other 50% of 
mice that developed tumors while still receiving daily 
momelotinib treatment had significantly reduced tumor 
burden compared to control and Group 2 mice. These mice 
also had a significantly greater overall survival compared 
to mice in Phase 2 where the treatment was terminated. 
This demonstrates that the ongoing momelotinib 
treatment effectively maintained the suppression of 
tumor growth and progression in mice. Nonetheless, 
the 50% unresponsive mice group, presumably resistant 
to momelotinib treatment, that developed tumors 
showed levels of JAK2/STAT3 activation, c-Kit and 
Oct3/4 expression that were similar to their paclitaxel+ 
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momelotinib counterparts in Phase 1 which also showed 
similar tumor burden. Resistance to targeted therapies in a 
sub-population of cancer patients remains a major problem 
despite initial clinical responses [49, 50]. The mechanisms 
underlying resistance to momelotinib therapy may be due 
to activation of an alternative complementary pathway 
which may support the survival of momelotinib-resistant 
population. Cross-talks between signalling pathways have 
been demonstrated in many tumors [51].
This study highlights that the addition of 
momelotinib to current chemotherapy regimens may be 
a promising therapeutic approach for the treatment of 
advanced-stage ovarian cancer patients. In this context, 
momelotinib has recently undergone a Phase I/II clinical 
trial for myelofibrosis, a fatal myeloproliferative 
neoplasm driven by the constitutive activation of JAK2/
STAT3 pathway frequently caused by a JAK2V617F 
gain-of-function mutation which involves a valine-
to-phenylalanine modification at position 617 [52]. 
Ongoing treatment with momelotinib has shown low 
level of toxicity in myelofibrosis patients, and has also 
shown significant recuperation in spleen response rate 
with substantial improvement of symptoms within the 
first month of therapy [53]. Hence, this preliminary 
‘proof of concept’ study necessitates comprehensive 
evaluation of momelotinib in Phase 2 clinical trials 
in chemonaive and relapsed ovarian cancer patients. 
The proposed clinical outcome of paclitaxel and 
momelotinib-mediated therapy in ovarian cancer 
patients is illustrated in Figure 12.
MATERIALS AND METHODS
Cell lines
The human ovarian HEY cell line was derived 
from a human ovarian cancer xenograft originally grown 
from a peritoneal deposit of a patient with moderately 
differentiated papillary cystadenocarcinoma of the ovary 
[54]. The human ovarian clear cell adenocarcinoma 
cell line TOV21G was derived from grade 3, stage III, 
primary malignant adenocarcinoma from a patient who 
was not exposed to chemotherapy or radiation therapy 
[55]. The HEY cell line was grown in complete RPMI 
1640 (Sigma-Aldrich, Sydney, Australia) supplemented 
with 10% (v/v) heat inactivated foetal bovine serum 
(FBS) (Thermo Fisher Scientific, MA, USA), 2mM 
L-glutamine (Murdoch Childrens Research Institute, 
Victoria, Australia) and 1% (v/v) penicillin and 
streptomycin. The TOV21G cell line was maintained 
in 1:1 mixture of MCDB131 (Life Technologies, CA, 
USA) and Medium 199 (Lonza, Basel, Switzerland) 
supplemented with 15% (v/v) heat inactivated FBS 
(Thermo Fisher Scientific), 2mM L-glutamine and 1% 
(v/v) penicillin and streptomycin. Cells were routinely 
checked for mycoplasma infection.
Antibodies and reagents
Polyclonal antibody against phosphorylated 
(Tyr-705) STAT3 (P-STAT3), total STAT3 (T-STAT3), 
phosphorylated (Tyr-1007/1008) JAK2 (P-JAK2), total 
JAK2 (T-JAK2), EpCAM and CD117 (c-Kit) were 
obtained from Cell Signalling Technology (Beverly, MA, 
USA). Monoclonal antibody against CD133 was obtained 
from Miltenyl Biotec (Macquarie Park, NSW, Australia). 
Antibodies against Ki67, CA125, Oct3/4 CD117 (c-Kit) 
and CD31 used for immunohistochemistry were obtained 
from Ventana (Roche, Arizona, USA). Momelotinib was 
obtained from Dr Christopher Burns, Walter and Eliza 
Hall Institute of Medical Research, Melbourne, Australia.
Treatment of HEY and TOV21G cell lines with 
paclitaxel, momelotinib or a combination of both
Ovarian cancer HEY and TOV21G cell lines were 
treated with paclitaxel at a concentration at which 50% 
growth inhibition (GI50) was obtained (0.05μg/mL for HEY 
cells and 0.01μg/mL for TOV21G cells). The response 
of HEY and TOV21G cell lines in response to paclitaxel 
was determined by MTT assay at 24 hour as described 
previously [35]. This was to ensure that the surviving cells 
had been exposed to an adequate concentration of the drug, 
while ensuring sufficient cell numbers for in vitro analyses. 
For momelotinib treatment, cells were screened for the 
response to different concentrations of momelotinib in 
both cell lines, and the concentration that gave optimum 
inhibition of P-JAK2 and P-STAT3 in response to paclitaxel 
was selected in both cell lines (1μM for both cell lines).
Immunofluorescence analysis
Immunofluorescence was performed as described 
previously [2, 20]. Fluorescence imaging was visualized and 
captured using an Olympus CellR fluorescence microscope. 
Semi-quantitative analysis to assess fluorescence intensity 
was performed using the inbuilt CellR software.
SDS-PAGE and Western blot analysis
SDS-PAGE and Western blot was performed on the 
cell lysates as described previously [20].
Flow cytometry analyses
Flow cytometry was used to assess the expression 
of cell surface markers as described previously [2, 3]. 
Data was analysed using Cell Quest software (Becton-
Dickinson, Bedford, MA, USA).
Quantitative real time PCR (qRT-PCR) analysis
RNA extractions, cDNA synthesis and quantitative 
determination of mRNA levels of various genes were 
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performed as described previously [56]. The sequence 
of forward and reverse primers is described in Table 
1. Real time PCR was performed using the Applied 
Biosystems ABI 7900 HT Fast real-time machine. Yields 
were converted to femtograms (fg) based on the standard 
curve for each product and the resulting mRNA levels 
were normalized to the 18S mRNA level per sample. 
Each experiment was performed in triplicate on three 
independent biological samples.
Animal ethics statement
This study was carried out in strict accordance with 
the recommendations in the Guide for the Care and Use 
of the Laboratory Animals of the National Health and 
Medical Research Council of Australia. The experimental 
protocol was approved by the University of Melbourne’s 
Animal Ethics Committee (Project-1413207.1), and was 
endorsed by the Research and Ethics Committee of Royal 
Women’s Hospital Melbourne, Australia.
Animal studies
Female Balb/c nu/nu mice (age, 6–8 weeks) were 
obtained from the Animal Resources Centre, Western 
Australia. Animals were housed in a standard pathogen-
free environment with access to food and water. Animal 
experiments were performed on Balb/c nude mice as 
described below:
Experimental design
Briefly, female Balb/c nu/nu mice (age 6 - 8 
weeks) were injected ip with 5 x 106 viable ovarian 
cancer HEY cells, a dose previously shown to produce 
significant tumor burden [3]. After 19 days, mice 
were treated weekly with ip injection of paclitaxel at 
a concentration of 15mg/kg of mice bodyweight with 
or without momelotinib given daily at a concentration 
of 25mg/kg of mice bodyweight by oral gavage. Mice 
were inspected every 2 - 3 days and tumor formation 
was monitored by palpation in addition to the overall 
body condition and body weight until the pre-
determined endpoint was reached. Phase 1 and 2 studies 
were performed simultaneously, with a common control 
untreated group (n=4). At the endpoint, organs (such as 
liver, kidney, gastrointestinal tract, pancreas and spleen) 
and solid tumors were collected and processed for H&E 
and/or immunohistochemical analysis.
Phase 1 study
Nineteen days post-ip injection of HEY cells, mice 
were divided into three groups based on the treatment given: 
paclitaxel, momelotinib, and a combination of paclitaxel 
and momelotinib (n=4 control and n=3/treatment group). 
All treatments were maintained until the endpoint of control 
untreated mice was reached. At this point, all mice in Phase 
1 study were euthanized. Mice were monitored and weighed 
daily and any sign of tumor development was assessed by 
palpating the abdomen. Endpoint criteria included loss of 
body weight exceeding 20% of initial body weight and 
other physical parameters such as extension of abdomen 
anorexia and general patterns of diminished well-being 
such as abnormalities in respiration, motility, posture, and 
response to provocation [3, 20].
Phase 2 study
Nineteen days post-ip injection with HEY cells, 
mice were divided into three groups based on the treatment 
given: paclitaxel, momelotinib, and a combination of 
paclitaxel and momelotinib (n=4-5/group of paclitaxel 
or momelotinib treated mice or combined paclitaxel 
and momelotinib treated mice). All treatments were 
maintained until the endpoint of control untreated mice. 
At this point, the control untreated mice were euthanized 
and all treatments in other groups were terminated. Mice 
in the treatment group were inspected every 2 – 3 days 
until their individual endpoint were reached as described 
in Phase 1 study.
Phase 3 study
Nineteen days post-ip injection of HEY cells, all 
mice were treated with a combination of paclitaxel and 
momelotinib, except for the control untreated mice (n=9) 
and were divided into three groups (n=9/group). In Group 
1, all treatments were maintained until the endpoint 
of control untreated mice. At this point, the control 
untreated and Group 1 mice were euthanized. In Group 
2, all treatments were maintained until the endpoint of 
control untreated mice. At this point, all treatments were 
terminated but the treated mice were maintained and 
monitored until the end point was reached. In Group 3, all 
treatments were maintained until the endpoint of control 
untreated mice. At this point, only paclitaxel treatment 
was terminated while momelotinib only treatment 
was maintained by oral gavage. Mice in Group 3 were 
inspected every 2 – 3 days until their individual endpoint 
was reached, or until the designated endpoint of the 
experiment at 91 days post-inoculation.
Immunohistochemistry of mouse tumors
Hemotaxylin & Eosin (H & E) staining of mouse 
organs and tumors was performed by the staff at the 
Anatomical Pathology Laboratory Services at The 
Royal Children’s Hospital, Melbourne, Australia 
according to the standard H&E protocol [57]. 
Immunohistochemistry analysis of mouse tumors 
was performed on formalin fixed, paraffin embedded 
4 μm sections of the xenografts and were stained 
using a Ventana Benchmark Immunostainer (Ventana 
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Medical Systems, Inc, Arizona, USA) as described 
previously [3, 20]. Negative controls were prepared 
by incubating each tumor section without primary 
antibodies. Sections of human breast tissue, high-
grade ovarian tumors and human tonsils were used 
as positive controls to determine the staining efficacy 
of primary antibodies. Immunohistochemistry images 
were taken using an Aperio ImageScope (Leica 
Microsystems, Mt Waverly, Australia) with the 
associated digital pathology viewing software. DAB 
staining was measured using the open source image 
processing package Fiji (https://fiji.sc/) with a plug-in 
developed to recognize DAB staining for 10 randomly 
captured images per section. DAB staining intensity 
of the negative control was subtracted from the DAB 
staining of the antibody of interest to get a measure of 
DAB staining of interest.
Statistical analysis
All results are presented as the mean ± standard error 
of the mean (SEM) of three independent experiments unless 
otherwise indicated. Comparisons between more than two 
groups with one independent variable were analysed using 
One-Way ANOVA with Tukey’s post hoc test. Comparisons 
of survival curves were analysed using Kaplan-Meier curves 
with Log-rank test. Each in vitro experiment was performed at 
least three times with a minimum of three biological replicates. 
Data was analysed using Microsoft Excel 2010 and GraphPad 
Prism Software (version 6). A probability level of p<0.05 was 
adopted throughout to determine statistical significance.
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